Sleep Disorders

Findings from the Jazz DUET study presented at SLEEP 2025 showed that low-sodium oxybate reduced daytime sleepiness and improved sleep parameters in patients with narcolepsy types 1 and 2.

The neuroscientist and physician at Mount Sinai explored the role of sleep-dependent brain clearance in Alzheimer disease and how emerging research is challenging longstanding assumptions.

Data from a pair of phase 3 trials suggest that tirzepatide treatment may improve patient-reported measures of sleepiness in individuals with obstructive sleep apnea and obesity.

New phase 2 trial data presented at SLEEP 2025 suggest TAK-861 significantly decreased microsleep frequency and delayed onset of first microsleep in individuals with narcolepsy type 1.

New analysis reveals insights on hypnagogic and hypnopompic hallucinations in narcolepsy patients treated with once-nightly sodium oxybate.

A newly presented actigraphy-based algorithm demonstrated high accuracy in detecting daytime naps, offering insights into napping behavior changes in patients with narcolepsy type 1.

A recent analysis reveals the safety profile of once-nightly sodium oxybate for narcolepsy, highlighting low discontinuation rates and common adverse events.

A new study presented at SLEEP 2025 reported that more than one-quarter of pregnant women experienced restless legs syndrome, with prior history of the condition emerging as a significant risk factor.

New research reveals solriamfetol significantly enhances neuropsychological outcomes in patients with obstructive sleep apnea and excessive daytime sleepiness.

Recent research reveals that transcranial direct current stimulation (tDCS) shows no significant benefits for insomnia, highlighting the need for larger studies.

A newly presented study at SLEEP 2025 explored the practicality of various methods, such as the Apple Watch and polysomnogram, for assessing sleep in pediatric patients with Lennox-Gastaut syndrome.

A new study evaluates the effectiveness and safety of once-nightly sodium oxybate for narcolepsy, aiming to enhance patient treatment experiences.

A phase 2 study shows samelisant significantly reduces excessive daytime sleepiness in narcolepsy, paving the way for further research and development.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the care of parasomnias.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 30, 2025.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 23, 2025.

Apnimed's AD109 shows promise in treating obstructive sleep apnea, achieving significant results in a landmark Phase 3 trial, paving the way for FDA approval.

A recent interim analysis of a 5-year observational study showed sustained benefit of pitolisant in reducing excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Over a 4-week treatment period, daridorexant outperformed placebo on several subjective sleep and nocturia assessments, while maintaining a good safety and tolerability profile.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 25, 2025.

The director of sleep medicine at Nemours Children's Health in Florida talked about the growing role of multidisciplinary care and novel therapies in managing pediatric sleep disorders.

Data suggest no significant differences in comorbidity rates in a newly published study, highlighting dosing challenges and treatment patterns in patients receiving immediate-release sodium oxybate.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Cleveland Clinic’s $1.1 billion Neurological Institute, opening in 2027, will revolutionize neurological care with a state-of-the-art, patient-centered design integrating advanced technology and innovative care solutions.

Here's some of what is coming soon to NeurologyLive® this week.

A recent post hoc analysis of the REST-ON trial reported that once-nightly sodium oxybate did not worsen the apnea-hypopnea index in individuals with narcolepsy with no or mild sleep apnea.

Here's some of what is coming soon to NeurologyLive® this week.